Literature DB >> 31956527

Prostate cancer evaluation using PET quantification in 68Ga-PSMA-11 PET/MR with attenuation correction of bones as a fifth compartment.

Liran Domachevsky1,2, Natalia Goldberg1, Miguel Gorenberg3, Hanna Bernstine1,2, David Groshar1,2, Onofrio A Catalano4.   

Abstract

BACKGROUND: Tissues with low magnetic resonance (MR) signals, such as bones and lungs differ considerably in their attenuation properties, requiring special considerations for attenuation correction. We evaluated the impact of using the five-compartment segmentation model, which incorporates bones, in 68Ga-PSMA-11 PET/MR studies in patients undergoing evaluation for prostate cancer.
METHODS: Prostate cancer patients underwent dedicated prostate 68Ga-PSMA-11 PET/MR followed by whole-body 68Ga-PSMA-11 PET/CT. Coronal µmap images of the pelvis derived from four- and five-compartment segmentation models of magnetic resonance attenuation correction (MRAC) were produced. Standardized uptake values (SUV) calculated by the four and five-compartment MRAC models and by computed tomography attenuation correction (CTAC) were compared and correlated in normal prostate tissue, gluteus muscle, sacrum, intra-prostatic lesions and metastases (i.e., bone lesions and involved lymph nodes), and prostatic lesions to gluteus (L/G) ratio.
RESULTS: Twenty-six patients (mean age 69.4±9.3 years) were included in the study. Twenty-five patients presented for prostate cancer staging and one patient was evaluated for recurrent disease. There was a statistically significant difference between SUVs of the gluteus, sacrum, prostatic lesions and normal prostate tissue measured by the four-compartment vs. the five-compartment MRAC models, with a medium effect size. Very good to good correlation between SUV measured using the four-compartment MRAC model and SUV measured using the five-compartment model were noted in all lesional and non-lesional areas. Very good to good correlation was noted between four-compartment MRAC and CTAC SUVs of prostatic lesions and L/G ratio and between five-compartment MRAC and CTAC SUVs of prostatic lesions, L/G ratio and metastatic lesions.
CONCLUSIONS: 68Ga-PSMA-11 PET/MR using the five-compartment segmentation model affects SUV measurements in prostate lesions and in the normal prostate and therefore patient follow-up studies must be conducted using the same segmentation model. 2020 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Bones; positron emission tomography computed tomography (PET CT); prostatic neoplasms

Year:  2020        PMID: 31956527      PMCID: PMC6960422          DOI: 10.21037/qims.2019.11.19

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  15 in total

1.  The effect of errors in segmented attenuation maps on PET quantification.

Authors:  Vincent Keereman; Roel Van Holen; Pieter Mollet; Stefaan Vandenberghe
Journal:  Med Phys       Date:  2011-11       Impact factor: 4.071

2.  Early 68GA-PSMA PET/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET/CT.

Authors:  L Domachevsky; H Bernstine; N Goldberg; M Nidam; D Stern; J Sosna; D Groshar
Journal:  Clin Radiol       Date:  2017-07-14       Impact factor: 2.350

3.  One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer.

Authors:  Mark Thalgott; Charlotte Düwel; Isabel Rauscher; Matthias M Heck; Bernhard Haller; Andrei Gafita; Jürgen E Gschwend; Markus Schwaiger; Tobias Maurer; Matthias Eiber
Journal:  J Nucl Med       Date:  2018-05-24       Impact factor: 10.057

4.  Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.

Authors:  Liran Domachevsky; Natalia Goldberg; Hanna Bernstine; Meital Nidam; David Groshar
Journal:  Eur Radiol       Date:  2018-05-30       Impact factor: 5.315

5.  Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.

Authors:  Sonya Youngju Park; Claudia Zacharias; Caitlyn Harrison; Richard E Fan; Christian Kunder; Negin Hatami; Frederik Giesel; Pejman Ghanouni; Bruce Daniel; Andreas M Loening; Geoffrey A Sonn; Andrei Iagaru
Journal:  Radiology       Date:  2018-05-22       Impact factor: 11.105

6.  Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.

Authors:  Mohammad Al-Bayati; Johannes Grueneisen; Susanne Lütje; Lino M Sawicki; Saravanabavaan Suntharalingam; Stephan Tschirdewahn; Michael Forsting; Herbert Rübben; Ken Herrmann; Lale Umutlu; Axel Wetter
Journal:  Urol Int       Date:  2018-01-25       Impact factor: 2.089

7.  The Effect of Including Bone in Dixon-Based Attenuation Correction for 18F-Fluciclovine PET/MRI of Prostate Cancer.

Authors:  Mattijs Elschot; Kirsten M Selnæs; Håkon Johansen; Brage Krüger-Stokke; Helena Bertilsson; Tone F Bathen
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

8.  Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.

Authors:  Axel Martinez-Möller; Michael Souvatzoglou; Gaspar Delso; Ralph A Bundschuh; Christophe Chefd'hotel; Sibylle I Ziegler; Nassir Navab; Markus Schwaiger; Stephan G Nekolla
Journal:  J Nucl Med       Date:  2009-03-16       Impact factor: 10.057

9.  Impact of improved attenuation correction featuring a bone atlas and truncation correction on PET quantification in whole-body PET/MR.

Authors:  Mark Oehmigen; Maike E Lindemann; Marcel Gratz; Julian Kirchner; Verena Ruhlmann; Lale Umutlu; Jan Ole Blumhagen; Matthias Fenchel; Harald H Quick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-09       Impact factor: 9.236

10.  Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.

Authors:  Martin T Freitag; Jan P Radtke; Boris A Hadaschik; A Kopp-Schneider; Matthias Eder; Klaus Kopka; Uwe Haberkorn; Matthias Roethke; Heinz-Peter Schlemmer; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-28       Impact factor: 9.236

View more
  6 in total

1.  Unexpected discovery of prostatic diffuse large B-cell lymphoma after thulium laser vaporization in a patient with Waldenstrom macroglobulinemia.

Authors:  Jialei Wang; Huilei Yan; Shuyan Tian; Lei Qin; Yunbo Ma
Journal:  Quant Imaging Med Surg       Date:  2022-01

2.  Efficacy of 68Ga-PSMA-11 PET/CT with biparametric MRI in diagnosing prostate cancer and predicting risk stratification: a comparative study.

Authors:  Yi Nuo; Aimei Li; Lulu Yang; Hailin Xue; Feng Wang; Liwei Wang
Journal:  Quant Imaging Med Surg       Date:  2022-01

3.  Value of transrectal contrast-enhanced ultrasound with clinical indicators in the prediction of bone metastasis in prostate cancer.

Authors:  Hua Hong; Danyan Liang; Qian Liu; Guozhu Wu; Ran Sun; Juzhen Liu; Feng Wang; Fang Wang
Journal:  Quant Imaging Med Surg       Date:  2022-03

Review 4.  PET/MRI in prostate cancer: a systematic review and meta-analysis.

Authors:  Laura Evangelista; Fabio Zattoni; Gianluca Cassarino; Paolo Artioli; Diego Cecchin; Fabrizio Dal Moro; Pietro Zucchetta
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-08       Impact factor: 9.236

5.  An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.

Authors:  Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-22       Impact factor: 9.236

6.  The impact of MR-based attenuation correction in spinal cord FDG-PET/MR imaging for neurological studies.

Authors:  Valentina Brancato; Pasquale Borrelli; Vincenzo Alfano; Marco Picardi; Mario Mascalchi; Emanuele Nicolai; Marco Salvatore; Marco Aiello
Journal:  Med Phys       Date:  2021-09-13       Impact factor: 4.506

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.